BioInItaly Newsletter

La vetrina del biotech italiano all’estero
  • 31 gen, 2013
    Bausch + Lomb Initiates Phase 3 Program for Glaucoma Drug Candidate Licensed from Nicox
    Aptuit signs agreements with Alios BioPharma and Aegerion Pharmaceuticals
    Diagnosis of rheumatoid arthritis: a new kit from the collaboration between Toscana Biomarkers and AMAR Immunodiagnostics soon on the Indian market
    Aptalis Pharma, Inc. Announces Results of Phase 3 Studies of Aeroquin(TM) (Levofloxacin Solution for Inhalation) Among Patients With Cystic Fibrosis and Chronic Lung Infection
    Dako enters collaboration with Eli Lilly and Company for development of companion diagnostics
    Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin
    Axxam announces the appointment of Dr. Doris Hafenbradl as Vice-President, Discovery Services
  • 03 dic, 2012
    Eporgen’s portfolio company Genovax sells GX301, its clinical-stage therapeutic vaccine for the treatment of various types of cancer, to Mediolanum Farmaceutici
    TOP srl announces a collaboration with Charles River Laboratories International for the marketing and sales in North America (USA and Canada) of its products.
  • 05 nov, 2012
    Collaboration agreement between Telethon Foundation and Rare Partners
    Development and validation of a new kit for the detection of deletions in the AFZ locus associated with male infertility, based on Reverse Line Blot Technique
    The European Institute of Oncology aims to develop a localized and more tolerable radiotherapy for breast cancer
    Cell Therapeutics’ Unique Orally Available, Multi-Kinase Inhibitor CT-1578
    ABRAXANE the first Nano-chemo target therapy already approved for the treatment of metastatic breast cancer  meets Primary Endpoint of Progression-Free Survival in Phase III Chemotherapy-Naïve Metastatic Melanoma Study
    ViroStatics AV-HALT Phase 2a Study in HIV/AIDS Paper Published in PLoS ONE
    Nicox launches AdenoPlus(TM) in the United States
  • 03 ott, 2012
    AIFA - ISS – Assobiotec sign an agreement to stimulate the clinical trials in the field of biotechnology in Italy
    Servier concludes a collaboration and license agreement with EOS for its antitumor drug E-3810
    Cell Therapeutics Announces European Launch of Pixuvri® for Treatment of Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphoma
    Cell Therapeutics OPAXIO Receives Orphan Drug Designation for Malignant Brain Cancer from FDA
    Adienne moves offices
  • 03 lug, 2012
    The European Patent Office grants MolMed a new patent on its anticancer drug NGR-hTNF
    Cell Therapeutics Completes Acquisition of Pacritinib a Highly Selective JAK2 Inhibitor
    Mediapharma established in Chieti
    NicOx signs worldwide licensing agreement with Rapid Pathogen Screening, Inc. for ophthalmic diagnostics
    Medi Service: signal detection
    Toscana Biomarkers Coordinator of GAPAID project, ranked 12th in "Research for SMEs" call of the 7° Framework Programme
    New initiatives from Fondazione Filarete
    The Distretto Toscano Scienze della Vita/Tuscany Life Science Cluster is looking for a Temporary Manager
  • 01 giu, 2012
    A strategic alliance on anti-cancer drugs between NERVIANO and IEO
    Cell Therapeutics’ Pixuvri Approved in European Union as monotherapy to treat adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-Cell Lymphomas
    Cell Therapeutics enters into agreement to acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3 Candidate for Myelofibrosis
    New England Journal of Medicine reports on three Phase III Revlimid (lenalidomide) trials in patients with newly diagnosed multiple myeloma
  • 02 mag, 2012
    Abcodia and Biouniversa announce collaboration on BAG3 biomarker for the early detection of pancreatic cancer
    A collaboration between Heinz and IEO gives birth to a new generation of infant food
    NicOx appoints Philippe Masquida EVP, Managing Director of European Operations
  • 01 apr, 2012
    NicOx, Bausch + Lomb Glaucoma Candidate BOL-303259-X Meets Primary Endpoint in Phase 2b Study
    NicOx enters into option agreement to acquire Altacor as a first step towards building an international ophthalmology business
    Axxam receives EUR 2.3 million grant from the Italian Ministry of Research to support innovative drug discovery programs
    Aptuit Verona invests on a preclinical cardiac safety panel
    BioInItaly 2012: The Italian Biotech Investment Forum, where biotech meets investors
  • 01 mar, 2012
    Dompé to acquire 100% of Anabasis, an Italian biopharmaceutical ophthalmology company
    The Link Campus University has established the BioLink Institute in Rome
    European Medicines Agency's Committee For Medicinal Products For Human Use issues positive opinion for conditional Approval on marketing authorization application for Pixuvri
    BioInItaly 2012: The Italian Biotech Investment Forum, where biotech meets investors
  • 01 feb, 2012
    Rheumatoid arthritis: soon on the market a new kit for the diagnosis
    thanks to the collaboration between Toscana Biomarkers and DIESSE Ricerche
    TTFactor and OncoMed Pharmaceuticals Inc. sign an agreement for advancing novel cancer therapies through IEO scientific expertise
    AB ANALITICA launches a simple and fast kit for the detection of all HLA haplotypes associated with Celiac Disease, using Reverse Line Blot Protocol and dedicated software for interpretation of results
    Axxam awarded with EUR 0.5 million by the Lombardy Region to support an innovative high throughput method for  early “in vitro” safety risk assessment of compounds.
    BioInItaly 2012: The Italian Biotech Investment Forum, where biotech meets investors
  • 08 gen, 2012
    A Strategic International Health Care Event (10th February 2012, Milano - Italy)
    Italian Biotech meets Investors in Milan (BioInItaly, April 18-19)
    UK–Italy Business Awards Ceremony
  • 02 dic, 2011
    BioInItaly 2012: The Italian Biotech Investment Forum, where biotech meets investors